{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T19:42:45Z","timestamp":1781984565855,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00555","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T02:19:39Z","timestamp":1544062779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia"],"prefix":"10.3389","volume":"8","author":[{"given":"Sara","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ciabatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Perutelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Del Genio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Montali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Barachini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Immacolata","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Valetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Salehzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Mattii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev.me.40.020189.000553","article-title":"Molecular pathogenesis of Ph-positive leukemias","volume":"40","author":"Clark","year":"1989","journal-title":"Annu Rev Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12885-015-1857-x","article-title":"The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma\u2013a Swedish population-based study","volume":"15","author":"Mohammadi","year":"2015","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12885-016-2635-0","article-title":"In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants","volume":"16","author":"Soverini","year":"2016","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechamisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HP.S51812","article-title":"One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a \u201chypoxic\u201d environment","volume":"2","author":"Rovida","year":"2014","journal-title":"Hypoxia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1080\/15384101.2015.1006053","article-title":"gDNA Q-PCR for clinical monitoring of CML","volume":"14","author":"Porta","year":"2015","journal-title":"Cell Cycle"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-017-0642-1","article-title":"Treatment-free remission: a new therapeutic goal in chronic myelogenous leukemia","volume":"19","author":"Elsayed","year":"2017","journal-title":"Curr Oncol Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"19","author":"Laneuville","year":"2018","journal-title":"Curr Treat Options Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia","volume":"44","author":"Valent","year":"2014","journal-title":"Eur J Clin Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission","volume":"8","author":"Bocchia","year":"2018","journal-title":"Front Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2217\/epi.15.35","article-title":"Polycomb genes are associated with response to imatinib in chronic myeloid leukemia","volume":"7","author":"Crea","year":"2015","journal-title":"Epigenomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11899-011-0085-y","article-title":"In search of CML stem cells' deadly weakness","volume":"6","author":"Pellicano","year":"2011","journal-title":"Curr Hematol Malig Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","article-title":"Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization","volume":"94","author":"Cross","year":"2015","journal-title":"Ann Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bcmd.2014.07.002","article-title":"BMI1 gene expression in myeloid leukemias and its impact on prognosis","volume":"53","author":"Saudy","year":"2014","journal-title":"Blood Cells Mol Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.bbrc.2013.05.079","article-title":"MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2","volume":"436","author":"Yang","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1084\/jem.20111709","article-title":"Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes","volume":"209","author":"Oguro","year":"2012","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1080\/10428194.2017.1410883","article-title":"Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival","volume":"59","author":"AlJohani","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1038\/s41598-017-02800-2","article-title":"miR-15a\/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.21873\/anticanres.12052","article-title":"BMI1 inhibitors down-regulate NOTCH signaling and suppress proliferation of acute leukemia cells","volume":"37","author":"Ohtaka","year":"2017","journal-title":"Anticancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"103731","DOI":"10.18632\/oncotarget.21909","article-title":"The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains","volume":"8","author":"Alzrigat","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-0962","article-title":"High BCR-ABL\/GUSIS levels a diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib","volume":"23","author":"Vigneri","year":"2017","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T02:19:41Z","timestamp":1544062781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":27,"alternative-id":["10.3389\/fonc.2018.00555"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00555","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"article-number":"555"}}